Cagrilintide · Research brief
Retatrutide (LY3437943): What Research Shows in 2026
Short answer
Retatrutide is the first single-molecule triple hormone receptor agonist to reach registrational clinical trials, and that one structural fact explains why it generates more laboratory interest than almost any other metabolic peptide of the past decade. Semaglutide engages one receptor. Tirzepatide engages two.
Key takeaways
- Retatrutide, also designated LY3437943, is the first single-molecule agonist at three receptors, GIP, GLP-1 and glucagon, to reach registrational clinical trials.
- The glucagon receptor arm contributes hepatic energy expenditure and lipid mobilisation, which is what distinguishes retatrutide pharmacologically from dual agonists such as tirzepatide.
- Reported half-life sits in the region of six days, meaning several weeks pass before any given exposure tier reaches steady state.
- Gastrointestinal adverse events dominate the published safety profile, with heart rate increases at higher exposure tiers and reported cutaneous sensory events as the class-atypical findings.
- No head-to-head trial between retatrutide and tirzepatide exists in the published literature, so every comparative ranking currently rests on indirect network meta-analysis.
- HPLC purity analysis, mass spectrometry identity confirmation and a lot-numbered certificate of analysis are three separate checks, and none substitutes for the others.
Retatrutide is the first single-molecule triple hormone receptor agonist to reach registrational clinical trials, and that one structural fact explains why it generates more laboratory interest than almost any other metabolic peptide of the past decade. Semaglutide engages one receptor. Tirzepatide engages two. Retatrutide engages three, and the third one, the glucagon receptor, works in a direction that sounds counterintuitive until you look at the mechanism.
We supply research-grade peptides to laboratories, which means we read this literature the way a procurement scientist reads it: what was measured, in which population, over what duration, and with what analytical verification standing behind the material. Real Peptides does not carry retatrutide. What follows is a literature explainer, not a product page.
What is retatrutide?
Retatrutide, also designated LY3437943, is an investigational peptide that acts as an agonist at three receptors simultaneously: GIP, GLP-1 and glucagon. Phase 2 results have been published in the New England Journal of Medicine, the Lancet and Nature Medicine, with phase 3 programmes now reporting. No regulatory agency has approved it as a medicine.
The common oversimplification is that retatrutide is tirzepatide with one more receptor bolted on. That framing misses the point. Adding glucagon receptor agonism shifts the compound from a pure incretin mimetic into a combined incretin plus energy-expenditure agent, which is a different pharmacological class with a different adverse event profile and a different set of open safety questions. This page covers the mechanism receptor by receptor, what each published trial actually measured, the side effects and unknowns the literature reports, pharmacokinetics including half-life, how laboratories verify identity and purity, and where retatrutide sits against related compounds.
What does LY3437943 actually refer to?
LY3437943 is the development code Eli Lilly assigned to the molecule now known generically as retatrutide. It is a synthetic peptide built on a GIP-receptor-derived backbone, chemically modified with a fatty acid chain that promotes reversible binding to serum albumin. That acylation is the engineering decision that converts a peptide with a half-life measured in minutes into one measured in days.
The naming matters for anyone searching the literature. Early pharmacology papers and the first-in-human work use LY3437943 almost exclusively, while clinical publications from 2023 onward use retatrutide. A literature search that only covers one term misses roughly half the record. A 2025 review in Biomolecules provides a useful consolidated overview of how the molecule was designed and where it sits in obesity pharmacotherapy (PubMed 40563436).
Research groups evaluating the compound as a triple agonist rather than as another incretin analogue tend to frame the question differently from groups studying single-receptor peptides, which is a distinction we have covered separately in our breakdown of the triple-agonist research angle. The structural logic is straightforward once stated: three receptor engagements from one molecule removes the pharmacokinetic mismatch problem that arises when two separate compounds with different clearance curves are combined. That is the central design argument for retatrutide, and it is the reason the molecule attracted attention before any efficacy data existed.
How does the triple receptor mechanism work?
Retatrutide engages three distinct receptors, and each contributes something different. GLP-1 receptor agonism slows gastric emptying and amplifies satiety signalling through hypothalamic pathways. GIP receptor agonism modulates insulin secretion and appears to influence adipose tissue handling of nutrients. Glucagon receptor agonism is the unusual one, because glucagon is usually framed as the hormone that raises blood glucose.
The resolution is that glucagon receptor activation also increases hepatic energy expenditure and promotes mobilisation of stored hepatic lipid. In a molecule where GLP-1 and GIP agonism are simultaneously suppressing the glycaemic consequences, the glucagon arm contributes an energy-expenditure effect without the hyperglycaemia it would cause in isolation. A 2024 pharmacology review in the European Journal of Pharmacology walks through this three-way interaction in detail (PubMed 39515565).
Here is the detail most summaries skip. The three receptor affinities are not balanced. Retatrutide is reported as a potent GIP receptor agonist with comparatively weaker relative potency at GLP-1 and glucagon receptors, which means the pharmacological character of the molecule shifts as receptor occupancy changes rather than staying fixed. That non-linearity is why researchers tracking appetite-signalling endpoints and those tracking glycaemic endpoints can read the same trial and draw different conclusions about which receptor arm is doing the work.
In our experience reviewing peptide literature for laboratory clients, this is the single most misrepresented point about retatrutide. It is not three equal effects stacked together. It is a weighted blend, and the weighting is part of the compound's identity.
What published research exists on retatrutide so far?
The retatrutide evidence base moved from phase 1 to phase 3 unusually quickly, and the published record now spans obesity, type 2 diabetes, hepatic steatosis and body composition.
The anchor publication is the phase 2 obesity trial reported in the New England Journal of Medicine in 2023, a randomised placebo-controlled study running across 48 weeks (PubMed 37366315). It reported substantial mean body-weight reduction in the higher-exposure groups, with results that drew attention precisely because the magnitude exceeded what had been reported for dual agonists in comparable phase 2 work.
In parallel, a phase 2 trial in people with type 2 diabetes was published in the Lancet in 2023, comparing retatrutide against both placebo and an active comparator (PubMed 37385280). A later substudy from that programme examined body composition specifically, separating fat mass change from lean mass change, and appeared in Lancet Diabetes and Endocrinology in 2025 (PubMed 40609566). That substudy matters more than its citation count suggests, because body composition is where the glucagon arm would be expected to leave a distinctive fingerprint.
A phase 2a randomised trial in metabolic dysfunction-associated steatotic liver disease was published in Nature Medicine in 2024 (PubMed 38858523), reporting reductions in liver fat content. Phase 3 has now arrived: TRANSCEND-T2D-1, a double-blind randomised phase 3 trial in type 2 diabetes with inadequate glycaemic control on diet and exercise alone, was published in the Lancet in 2026 (PubMed 42250575). The TRIUMPH registrational programme, covering obesity, obstructive sleep apnoea and knee osteoarthritis, has its rationale and design paper in Diabetes, Obesity and Metabolism (PubMed 41090431).
What do the pooled analyses add?
Three independent synthesis papers now sit on top of the primary retatrutide trials, and they are the fastest route to understanding effect magnitude without reading every trial separately.
A 2024 systematic review and meta-analysis in Metabol Open pooled randomised controlled trial data on weight and metabolic markers (PubMed 39318607). A 2025 systematic review and meta-analysis in Proceedings (Baylor University Medical Center) assessed efficacy and safety specifically in the obesity setting (PubMed 40291085). Most usefully for comparative work, a 2025 Bayesian network meta-analysis in Obesity placed GLP-1 receptor agonists, dual agonists and retatrutide on a common comparative footing for weight reduction in adults with overweight or obesity (PubMed 40685589).
Network meta-analysis is the right tool here because head-to-head trials between retatrutide and tirzepatide do not exist in the published record. Indirect comparison is currently the only evidence-based way to rank them, and indirect comparison carries assumptions that a direct trial would not. Anyone drawing firm conclusions about which compound outperforms which should know that distinction before quoting a ranking. We have expanded on this comparative problem in our discussion of how the evidence stacks up between compounds and in the dual versus triple agonist breakdown.
What side effects and unknowns does the literature report?
Gastrointestinal adverse events dominate the reported safety profile across the retatrutide trials. Nausea, vomiting, diarrhoea and constipation were the most frequently reported events in both the phase 2 obesity trial (PubMed 37366315) and the phase 2 type 2 diabetes trial (PubMed 37385280), concentrated during the escalation phase rather than distributed evenly across the study period.
Two findings separate retatrutide from pure incretin agents. The trials reported increases in heart rate that were more pronounced at higher exposure tiers, which is pharmacologically consistent with glucagon receptor engagement rather than being an unexplained signal. The phase 2 obesity publication also described cutaneous sensory events, an uncommon observation in this drug class.
The honest part is the unknown column. Long-term cardiovascular outcome data for retatrutide does not yet exist in published form. Durability beyond trial duration is uncharacterised. The thyroid C-cell safety questions that attach to the incretin class generally have not been independently resolved for this molecule, a topic we treat separately in our review of carcinogenicity questions raised about the class. Combination behaviour is likewise unstudied, which is worth noting for anyone reading speculative material on combining it with other peptides, on overlap with tirzepatide, on pairing with tesamorelin, on BPC-157 pairing claims, on CJC-1295 pairing claims, or on androgen co-exposure questions. None of those combinations has a controlled trial behind it.
What is the reported half-life of retatrutide?
Retatrutide has a reported half-life in the region of six days, a consequence of the albumin-binding fatty acid modification that keeps the peptide in circulation rather than allowing rapid renal and enzymatic clearance. That multi-day elimination profile is why the published trials were designed around weekly intervals rather than daily ones (PubMed 39515565).
The practical implication for research interpretation is steady-state timing. With a half-life around six days, plasma concentrations approach steady state after roughly four to five half-lives, meaning several weeks pass before a given exposure tier reflects its full pharmacological effect. This is precisely why the trial programmes used ascending-tier designs over many weeks rather than evaluating a fixed exposure from week one, and why short-duration studies would systematically under-read the compound.
The same arithmetic runs in reverse during washout. Clearance to below detectable pharmacological activity takes weeks, not days, which is a design constraint for any crossover protocol. Researchers asking about interval frequency in study design or about circadian timing considerations are really asking a pharmacokinetic question, and the six-day figure answers most of it. Separately, oral bioavailability for a peptide of this size and structure is negligible without a permeation-enhancer formulation, which is the short answer behind the recurring oral-route questions.
How do researchers verify a retatrutide vial?
Three analytical documents separate verified research material from an unknown white powder, and every reputable supplier should produce all three on request.
HPLC purity analysis, usually reversed-phase high-performance liquid chromatography, quantifies the percentage of the sample that is the intended peptide versus truncated sequences, deletion sequences and synthesis byproducts. Research-grade peptides are typically specified at 98 percent or higher purity. A certificate without a chromatogram attached is an assertion, not a measurement.
Mass spectrometry confirms identity rather than purity. It verifies that the observed molecular weight matches the theoretical molecular weight of the declared sequence. Purity without identity is meaningless, because a vial can be 99 percent pure something else. The two tests answer different questions and neither substitutes for the other.
The certificate of analysis ties the two together with a batch or lot number that traces the tested material to the vial in hand. The failure mode we see constantly is a generic certificate with no lot reference, which cannot be matched to any specific production run. We publish batch-traceable certificates of analysis for every compound in our own catalogue, and the logic applies identically to any supplier under evaluation. For deeper treatment of sourcing standards, see our guides to what separates research peptide suppliers, third-party tested sourcing in 2026, research-grade quality assessment and why a certificate should accompany every order.
How is lyophilised peptide handled in a laboratory?
Lyophilised peptide powder is considerably more stable than solubilised peptide, which is why nearly every supply chain in this category ships it freeze-dried. Standard laboratory practice stores lyophilised material frozen, commonly at minus 20 degrees Celsius for medium-term storage and minus 80 degrees Celsius for long-term archival, protected from light and moisture.
Moisture is the underrated threat. Lyophilised peptides are hygroscopic, and the most common handling error is opening a cold vial in ambient air, which allows condensation to form on and inside the vial. That water initiates hydrolysis of the peptide backbone long before any visible change appears. Allowing a sealed vial to equilibrate to room temperature before opening prevents it, and costs nothing but patience.
Once in solution, stability drops sharply and refrigerated storage becomes the working standard with a much shorter usable window. Repeated freeze-thaw cycling degrades peptides through ice-crystal-driven aggregation, so single-use aliquoting is standard practice in well-run laboratories. Errors at the solubilisation step are where most material is quietly ruined, which we cover in detail in our guide to reconstitution errors that compromise a sample, alongside practical notes on cold-chain integrity during transport and on research material logistics.
What is the legal and research-use-only status?
Retatrutide is an investigational compound. It is not approved as a medicine by the FDA, the EMA or any comparable regulatory authority, and it holds no marketing authorisation anywhere. Material offered by chemical suppliers is sold under research-use-only terms, which is a legally distinct category from a pharmaceutical product.
All compounds discussed on this page are sold for research use only and are not for human consumption.
That status carries specific consequences. Research-use-only material is not manufactured under the same regulatory framework as an approved drug product, is not subject to regulatory batch release, and carries no approved labelling. Because retatrutide remains investigational and under patent, questions about whether it can be compounded and about online availability have regulatory answers that differ from those for shortage-listed approved molecules. Institutional buyers are responsible for confirming their own compliance position, including import rules that vary by shipping destination.
Nothing on this page is medical guidance. Anyone with questions about metabolic health should raise them with a licensed physician, and anyone conducting approved animal research should work with a qualified veterinarian under their institutional protocol.
How does it compare with tirzepatide, semaglutide and cagrilintide?
The table below places retatrutide alongside three related compounds on the dimensions that actually differ: receptor targets, regulatory position and the depth of published evidence behind each.
| Compound | Receptor targets | Regulatory status (2026) | Published evidence depth | Bottom line for researchers |
|---|---|---|---|---|
| Retatrutide (LY3437943) | Triple: GIP, GLP-1 and glucagon receptors | Investigational, no marketing authorisation anywhere | Phase 2 published across obesity, type 2 diabetes and steatotic liver disease, with phase 3 now reporting | The broadest mechanism in the class and the most interesting unanswered questions, but no long-term outcome data yet exists |
| Tirzepatide | Dual: GIP and GLP-1 receptors | Approved medicine in multiple jurisdictions | Large completed phase 3 programme with outcome data | The closest structural relative and the most common indirect comparator, since no head-to-head trial against retatrutide is published |
| Semaglutide | Single: GLP-1 receptor | Approved medicine in multiple jurisdictions | The deepest evidence base in the class, including cardiovascular outcomes | The reference standard against which everything else is measured, mechanistically the simplest of the four |
| Cagrilintide | Amylin and calcitonin receptor agonist, a different hormone family entirely | Investigational | Phase 2 published, frequently studied in combination rather than alone | Not a competitor to retatrutide so much as a different mechanistic axis, which is why combination designs dominate its literature |
For a fuller treatment of the amylin axis against the incretin axis, see our cagrilintide comparison, and for the broader metabolic research framing see our overview of metabolic health research questions.
What If: Laboratory Handling Scenarios
What if a lyophilised vial arrives at ambient temperature?
Document the excursion, then assess against the supplier's stated stability data before assuming the material is compromised. Lyophilised peptides tolerate short ambient excursions considerably better than solubilised peptides, because the rate-limiting degradation pathways require water. The real risk is a prolonged excursion combined with humidity exposure, which neither visual inspection nor a simple solubility check will reveal.
What if the certificate lists purity but no mass spectrometry?
Treat it as an incomplete document and request the mass spectrometry data before proceeding. HPLC purity tells you how much of the sample is one dominant species; it does not confirm that the species is the declared molecule. A sample can return 99 percent purity on chromatography while the dominant peak is a different peptide entirely.
What if the powder looks like a thin film instead of a cake?
A collapsed or filmy appearance usually reflects the lyophilisation cycle and the fill volume rather than a degraded product. Very small fill quantities frequently present as a translucent film on the vial wall, which alarms first-time buyers unnecessarily. Appearance is a weak quality signal at best; the certificate of analysis and lot traceability are the signals that carry information.
The blunt truth about retatrutide hype
Here is the honest answer: the published retatrutide data is genuinely striking, and the internet commentary around it is still well ahead of the evidence. Phase 2 efficacy is not durability. Phase 2 safety is not outcome safety. The cardiovascular outcome data that eventually defined semaglutide's clinical position simply does not exist for retatrutide yet, and nobody currently writing about it knows how the glucagon arm behaves over a multi-year horizon. The mechanism is the most interesting in the class. The evidence base is the youngest in the class. Both statements are true simultaneously, and most content on this compound only tells you one of them.
How we researched this page
Every study claim on this page is linked inline to its PubMed record, drawn from peer-reviewed publications in the New England Journal of Medicine, the Lancet, Lancet Diabetes and Endocrinology, Nature Medicine, Obesity, Biomolecules, the European Journal of Pharmacology, Diabetes Obesity and Metabolism, Metabol Open, Proceedings (Baylor University Medical Center) and Expert Opinion on Investigational Drugs, including the 2023 commentary summarising early promise in obesity and type 2 diabetes (PubMed 37947489). We conducted no first-party testing on retatrutide and make no first-party analytical claims about it, because we do not stock it. Where the literature is silent, we have said so rather than filling the gap with inference.
For related reading across our research library, our team maintains deeper explainers on supplier evaluation standards, certificate-backed sourcing, reconstitution handling errors, research access logistics, compounding status and the full cagrilintide against triple-agonist comparison.
Retatrutide occupies an unusual position in peptide research right now: a molecule with enough published data to be taken seriously and not nearly enough to be understood. The three-receptor design solved a real pharmacokinetic problem, and in solving it, created a new set of questions about what sustained glucagon receptor engagement does across years rather than weeks. That question will be answered by the phase 3 record, not by commentary. Until then, the most useful thing a researcher can do with retatrutide is read the primary trials in full and notice how carefully their authors hedge their own conclusions.
References
Peer-reviewed sources on Retatrutide indexed in PubMed, listed for research context. Real Peptides supplies Retatrutide for laboratory research use only.
- Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Proceedings (Baylor University. Medical Center), 2025. PMID 40291085. doi:10.1080/08998280.2025.2456441
- Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials. Journal of basic and clinical physiology and pharmacology, 2025. PMID 40728138. doi:10.1515/jbcpp-2025-0113
- A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. European journal of clinical pharmacology, 2024. PMID 38367045. doi:10.1007/s00228-024-03646-0
- Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. Metabolism open, 2024. PMID 39318607. doi:10.1016/j.metop.2024.100321
- Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, obesity & metabolism, 2026. PMID 41090431. doi:10.1111/dom.70209
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet (London, England), 2026. PMID 42250575. doi:10.1016/S0140-6736(26)00967-0
- Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules, 2025. PMID 40563436. doi:10.3390/biom15060796
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The lancet. Diabetes & endocrinology, 2025. PMID 40609566. doi:10.1016/S2213-8587(25)00092-0
Build a pack
Researching more than one compound?
Build a multi-vial pack and the discount applies automatically as you add vials.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA